Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00432458 · ClinicalTrials.gov registry record · Phase 3
Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma
A Phase 3 study of Multiple Myeloma and Plasma Cell Neoplasm, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 3
- Development phase
- 68
- Enrollment target
- 4
- Study locations
NCT00432458 is a Phase 3 study of Multiple Myeloma and Plasma Cell Neoplasm that has completed, run by Mayo Clinic. The registered enrollment target is 68 participants, below the 767-participant average among 26 other Multiple Myeloma and Plasma Cell Neoplasm trials with a reported enrollment target (91% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT00432458, a Phase 3 study of Multiple Myeloma and Plasma Cell Neoplasm, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 68 participants
- Enrollment target
- 4
- Study locations
Study Summary
RATIONALE: Zoledronate may prevent bone loss and stop the growth of cancer cells in bone. Thalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. It is not yet know whether giving zoledronate together with thalidomide is more effective than zoledronate alone in treating multiple myeloma. PURPOSE: This randomized phase III trial is studying zoledronate and thalidomide see how well they work compared with zoledronate alone in treating patients with early stage multiple myeloma.
Conditions Studied
Interventions
- DRUG Thalidomide
- DRUG zoledronic acid
Study Locations (4)
Arizona
- Mayo Clinic Scottsdale - Scottsdale
Florida
- Mayo Clinic - Jacksonville - Jacksonville
Minnesota
- Mayo Clinic Cancer Center - Rochester
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2003-07 |
| Est. Completion | 2012-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00432458
The ClinicalTrials.gov registry entry for NCT00432458 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 767-participant average among 26 other Multiple Myeloma and Plasma Cell Neoplasm trials with a reported enrollment target (91% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma and Plasma Cell Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Thalidomide is the first listed.
NCT00432458 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arizona, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00432458 about?
NCT00432458 is a clinical study titled "Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma". RATIONALE: Zoledronate may prevent bone loss and stop the growth of cancer cells in bone. Thalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. It is not yet know whether giving zoledronate together with thalidomide is more effective than zoledronate alone in treating...
What is the current status of trial NCT00432458?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 68 participants. The study started on 2003-07. Estimated completion is 2012-04.
What conditions does trial NCT00432458 study?
This clinical trial studies the following conditions: Multiple Myeloma and Plasma Cell Neoplasm.
What interventions are being tested in trial NCT00432458?
The interventions under investigation include: Thalidomide (DRUG), zoledronic acid (DRUG).
Who is sponsoring clinical trial NCT00432458?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00432458 being conducted?
This trial has 4 study locations across Arizona, Florida, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma and Plasma Cell Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
-
Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma
COMPLETED · Phase 3
-
Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
COMPLETED · Phase 3
-
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
COMPLETED · Phase 3
-
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
COMPLETED · Phase 3
-
Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.